GLP-1, GIP and glucagon receptor agonism · Peptide
Evidence gap: SC trials exist; an absolute human SC bioavailability percentage is not established in this import. Oral and IM PK are not established here.
Open in the interactive library →Compare with other compounds →
TRIUMPH-1 reported mean weight loss of 25.0% at 12 mg versus 3.9% with placebo at 80 weeks.
Context: 2,339 adults with obesity; phase 3 randomized trial.
Limitations: Trial methods are research context. No split-weekly regimen or peptide combination was validated by this trial.
A small MASLD substudy supports liver- and visceral-fat reductions with retatrutide alone.
Context: Human phase 2a substudy; 98 participants.
Limitations: These outcomes do not demonstrate extra benefit from adding tesamorelin.
In 338 randomized adults, least-squares mean weight reduction at week 24 was 7.2% (1 mg), 12.9% (combined 4 mg), 17.3% (combined 8 mg), and 17.5% (12 mg), versus 1.6% placebo; at week 48: 8.7%, 17.1%, 22.8%, and 24.2%, versus 2.1% placebo.
Context: Jastreboff et al., NEJM 2023; NCT04881760. Primary endpoint week 24; week 48 was secondary. BMI >=30 or 27 to <30 with weight-related condition.
Limitations: Group estimates are not individual predictions. Excluded populations and longer-term maintenance or clinical outcomes are not established by this 48-week Phase 2 trial.
Open this exact record in the library →Suggest a correctionSix retatrutide randomized groups: 1 mg; 4 mg starting 2 mg; 4 mg starting 4 mg; 8 mg starting 2 mg; 8 mg starting 4 mg; and 12 mg starting 2 mg, plus placebo. Treatment continued 48 weeks.
Context: Jastreboff et al., NEJM 2023, NCT04881760. Study arms and initial doses from methods, not personal titration instructions.
Limitations: Research regimens are not recommended individualized protocols. This abstract does not specify each escalation step or validate a nontrial formulation.
Open this exact record in the library →Suggest a correctionGastrointestinal adverse events were most common, dose related and generally mild to moderate; lower initial dose partially mitigated them. Dose-related heart-rate increases peaked at 24 weeks and declined afterward. Supplemental Table S14 reports hyperesthesia-related events including sensitive skin, allodynia and skin-burning symptoms.
Context: Safety monitoring in 48-week Phase 2 obesity trial; supplementary adverse-event tabulation is source-distinct from trial abstract.
Limitations: Adverse-event reports show association, not a diagnosis or proof of causation for an individual. Rare and long-term risks remain incompletely characterized.
Open this exact record in the library →Suggest a correctionRelative reductions in liver fat at 24 weeks averaged 81.4% (8 mg) and 82.4% (12 mg); at 48 weeks, the 12 mg group averaged 86.0%.
Context: NCT04881760 MASLD substudy; 98 adults; MRI-based liver-fat endpoint rather than histologic fibrosis reversal.
Limitations: Small imaging substudy with reduced follow-up sample; cannot infer individual outcomes or fibrosis reversal, and liver-fat improvement does not isolate the glucagon-receptor mechanism.
Open this exact record in the library →Suggest a correctionDistinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.
Context: Human · TRIUMPH-1: adults with obesity without diabetes; TRIUMPH-2: adults with obesity and type 2 diabetes
Human study regimen: Amount: 4 mg target; start 2 mg; Frequency: Once weekly; Duration: 80 weeks; Timing: Escalation every four weeks through applicable steps: 2 → 4 mg; Route: SC; Species: Human; Population: TRIUMPH-1: adults with obesity without diabetes; TRIUMPH-2: adults with obesity and type 2 diabetes
Limitations: Protocol details are preserved from the prior source review; supplements were not reopened. No split-weekly schedule was tested here.
Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.
Context: Human · TRIUMPH-1: adults with obesity without diabetes; TRIUMPH-2: adults with obesity and type 2 diabetes
Human study regimen: Amount: 9 mg target; start 2 mg; Frequency: Once weekly; Duration: 80 weeks; Timing: Escalation every four weeks through applicable steps: 2 → 4 → 6 → 9 mg; Route: SC; Species: Human; Population: TRIUMPH-1: adults with obesity without diabetes; TRIUMPH-2: adults with obesity and type 2 diabetes
Limitations: Protocol details are preserved from the prior source review; supplements were not reopened. No split-weekly schedule was tested here.
Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.
Context: Human · TRIUMPH-1: adults with obesity without diabetes; TRIUMPH-2: adults with obesity and type 2 diabetes
Human study regimen: Amount: 12 mg target; start 2 mg; Frequency: Once weekly; Duration: 80 weeks; Timing: Escalation every four weeks through applicable steps: 2 → 4 → 6 → 9 → 12 mg; Route: SC; Species: Human; Population: TRIUMPH-1: adults with obesity without diabetes; TRIUMPH-2: adults with obesity and type 2 diabetes
Limitations: Protocol details are preserved from the prior source review; supplements were not reopened. No split-weekly schedule was tested here.
Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.
Context: Human · Phase 2 obesity trial
Human study regimen: Amount: 1–12 mg study arms; Frequency: Once weekly; Duration: 48 weeks; Route: SC; Species: Human; Population: Phase 2 obesity trial
Limitations: The field guide provides a range, not a full arm-by-arm escalation table. Do not reconstruct missing steps.
Different receptor pathways do not prove synergy, muscle preservation, safety or optimal sequencing with tesamorelin.
Context: Mechanistic extrapolation from separate-drug results.
Limitations: No controlled combination study was identified in the imported review.
Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.
Context: Speaker describes “healthy optimizers”
Attributed proposal / anecdote: Amount: 1–2 mg; Route: Not documented; Population: Speaker describes “healthy optimizers”
Limitations: Frequency, route and cycle were not documented in this passage. Not a validated longevity regimen.
Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.
Context: Attributed research context; population or formulation not fully specified.
Attributed proposal / anecdote: Duration: Wait two to four weeks or longer before adding tesamorelin; Route: Not documented; Sequence: Introduce retatrutide first; add tesamorelin after the reported adjustment interval
Limitations: Sequential introduction may aid attribution but does not establish combination benefit, safety or an optimal interval.
This trial does not establish long-term cardiovascular event reduction, safety of nontrial products, oral bioavailability, twice-weekly superiority, or benefit/safety of combining retatrutide with tirzepatide or other peptide therapies.
Context: 338-person Phase 2 placebo-controlled trial funded by Eli Lilly; no active semaglutide or tirzepatide comparator.
Limitations: Absence of data is not proof of no benefit or harm. Avoid inferring personalized dosing and long-term outcomes from interim weight measures.
Open this exact record in the library →Suggest a correctionFDA classification and Lilly appeal determine market exclusivity and compounding
Context: Owner-approved social research lead; not independently substantiated.
Limitations: Legal and regulatory claims require independent docket and decision verification
Open this exact record in the library →Suggest a correctionRetatrutide acts on GLP-1, GIP and glucagon receptors
Context: Owner-approved social research lead; not independently substantiated.
Limitations: Mechanism broadly supported; comparative efficacy not established by receptor count alone
Open this exact record in the library →Suggest a correctionNonapproved reta vials are not FDA-regulated study drug
Context: Owner-published from the Jarvis queue onto Retatrutide. Evidence class U (Unresolved / evidence gap). This publication does not raise that class.
Limitations: FDA confirms retatrutide cannot be used in compounding and remains unapproved
Open this exact record in the library →Suggest a correction80-week weight reduction and glycaemic outcomes; dysesthesia, hypotension and gastrointestinal adverse events require safety review
Context: Owner-published from the Jarvis queue onto Retatrutide. Evidence class U (Unresolved / evidence gap). This publication does not raise that class.
Limitations: Trial-specific population; no generalization to non-study formulations; primary publication should be read in full before claims approval
Open this exact record in the library →Suggest a correctionMean weight changes -17.6%, -23.7%, -25.0% vs -3.9% placebo, treatment-regimen estimand; knee pain and apnea-hypopnea index improved in prespecified subgroups using distinct estimands
Context: Owner-published from the Jarvis queue onto Retatrutide. Evidence class U (Unresolved / evidence gap). This publication does not raise that class.
Limitations: Eli Lilly-funded Phase 3 trial; subgroup estimands differ from weight estimand; GI adverse events common; detailed full-text adverse event rates and PK not independently reviewed. PubMed abstract appears to contain a sign inconsistency for one hybrid-estimand apnea value; verify against full text before quoting.
Open this exact record in the library →Suggest a correctionTRANSCEND-CKD phase 2b randomized trial: measured GFR primary endpoint did not significantly improve at 24 weeks (reported difference -1.4 mL/min/1.73 m², 95% CI -9.2 to 6.3; p=0.714). Secondary albuminuria and other biomarker changes require scoped interpretation.
Context: Owner-published from the Jarvis queue onto Retatrutide. Evidence class U (Unresolved / evidence gap). This publication does not raise that class.
Limitations: ASN conference abstract, not full peer-reviewed results or poster PDF; 146 adults with CKD and overweight/obesity; UACR analysis restricted to 42 participants with elevated baseline albuminuria. Weekly subcutaneous investigational retatrutide titrated toward 12 mg; studied regimen only. No demonstrated long-term kidney protection; full adverse-event and PK results not independently verified. Compare NCT05936151 and subsequent primary publications.
Open this exact record in the library →Suggest a correctionOwner accepted PMID 39724554 as a source report. Evidence class stays Unresolved / evidence gap (U).
Context: Retatrutide literature queue. PMID 39724554. Reviewed 2026-10-17T12:44:35.822Z.
Limitations: Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.
Open this exact record in the library →Suggest a correctionOwner accepted PMID 42135195 as a source report. Evidence class stays Unresolved / evidence gap (U).
Context: Retatrutide literature queue. PMID 42135195. Reviewed 2026-10-17T12:47:22.621Z.
Limitations: Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.
Open this exact record in the library →Suggest a correctionOwner accepted PMID 42219269 as a source report. Evidence class stays Unresolved / evidence gap (U).
Context: Retatrutide literature queue. PMID 42219269. Reviewed 2026-10-18T01:26:49.270Z.
Limitations: Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.
Open this exact record in the library →Suggest a correctionOwner accepted PMID 42250575 as a source report. Evidence class stays Unresolved / evidence gap (U).
Context: Retatrutide literature queue. PMID 42250575. Reviewed 2026-10-20T03:58:20.004Z.
Limitations: Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.
Open this exact record in the library →Suggest a correctionOwner accepted PMID 42385950 as a source report. Evidence class stays Unresolved / evidence gap (U).
Context: Retatrutide literature queue. PMID 42385950. Reviewed 2026-10-20T03:58:35.071Z.
Limitations: Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.
Open this exact record in the library →Suggest a correctionOwner accepted PMID 42444567 as a source report. Evidence class stays Unresolved / evidence gap (U).
Context: Retatrutide literature queue. PMID 42444567. Reviewed 2026-10-18T07:01:42.362Z.
Limitations: Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.
Open this exact record in the library →Suggest a correctionOwner accepted PMID 42603384 as a source report. Evidence class stays Unresolved / evidence gap (U).
Context: Retatrutide literature queue. PMID 42603384. Reviewed 2026-10-20T03:58:47.536Z.
Limitations: Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.
Open this exact record in the library →Suggest a correctionOwner accepted PMID 42608321 as a source report. Evidence class stays Unresolved / evidence gap (U).
Context: Retatrutide literature queue. PMID 42608321. Reviewed 2026-10-20T03:58:59.092Z.
Limitations: Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.
Open this exact record in the library →Suggest a correctionOwner accepted PMID 42630988 as a source report. Evidence class stays Unresolved / evidence gap (U).
Context: Retatrutide literature queue. PMID 42630988. Reviewed 2026-10-20T03:59:32.696Z.
Limitations: Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.
Open this exact record in the library →Suggest a correctionOwner accepted PMID 42673585 as a source report. Evidence class stays Unresolved / evidence gap (U).
Context: Retatrutide literature queue. PMID 42673585. Reviewed 2026-10-21T07:11:32.217Z.
Limitations: Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.
Open this exact record in the library →Suggest a correctionOwner accepted PMID 42734711 as a source report. Evidence class stays Unresolved / evidence gap (U).
Context: Retatrutide literature queue. PMID 42734711. Reviewed 2026-10-21T07:11:43.911Z.
Limitations: Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.
Open this exact record in the library →Suggest a correctionOwner accepted PMID 42744908 as a source report. Evidence class stays Unresolved / evidence gap (U).
Context: Retatrutide literature queue. PMID 42744908. Reviewed 2026-10-21T07:12:03.821Z.
Limitations: Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.
Open this exact record in the library →Suggest a correctionOwner accepted PMID 42751099 as a source report. Evidence class stays Unresolved / evidence gap (U).
Context: Retatrutide literature queue. PMID 42751099. Reviewed 2026-10-21T07:12:36.734Z.
Limitations: Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.
Open this exact record in the library →Suggest a correctionOwner accepted PMID 42768195 as a source report. Evidence class stays Unresolved / evidence gap (U).
Context: Retatrutide literature queue. PMID 42768195. Reviewed 2026-10-21T07:12:52.265Z.
Limitations: Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.
Open this exact record in the library →Suggest a correctionOwner accepted PMID 42783450 as a source report. Evidence class stays Unresolved / evidence gap (U).
Context: Retatrutide literature queue. PMID 42783450. Reviewed 2026-10-21T07:13:15.899Z.
Limitations: Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.
Open this exact record in the library →Suggest a correctionOwner accepted PMID 42808923 as a source report. Evidence class stays Unresolved / evidence gap (U).
Context: Retatrutide literature queue. PMID 42808923. Reviewed 2026-10-21T07:13:34.205Z.
Limitations: Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.
Open this exact record in the library →Suggest a correctionOwner accepted PMID 42811393 as a source report. Evidence class stays Unresolved / evidence gap (U).
Context: Retatrutide literature queue. PMID 42811393. Reviewed 2026-10-21T07:17:01.298Z.
Limitations: Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.
Open this exact record in the library →Suggest a correctionOwner accepted PMID 42823062 as a source report. Evidence class stays Unresolved / evidence gap (U).
Context: Retatrutide literature queue. PMID 42823062. Reviewed 2026-10-21T07:16:34.683Z.
Limitations: Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.
Open this exact record in the library →Suggest a correctionOwner accepted PMID 42843917 as a source report. Evidence class stays Unresolved / evidence gap (U).
Context: Retatrutide literature queue. PMID 42843917. Reviewed 2026-10-21T07:16:20.236Z.
Limitations: Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.
Open this exact record in the library →Suggest a correctionOwner accepted PMID 42849462 as a source report. Evidence class stays Unresolved / evidence gap (U).
Context: Retatrutide literature queue. PMID 42849462. Reviewed 2026-10-21T07:16:05.971Z.
Limitations: Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.
Open this exact record in the library →Suggest a correctionOwner accepted PMID 42849689 as a source report. Evidence class stays Unresolved / evidence gap (U).
Context: Retatrutide literature queue. PMID 42849689. Reviewed 2026-10-21T07:15:53.310Z.
Limitations: Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.
Open this exact record in the library →Suggest a correctionOwner accepted PMID 42871568 as a source report. Evidence class stays Unresolved / evidence gap (U).
Context: Retatrutide literature queue. PMID 42871568. Reviewed 2026-10-21T07:14:14.262Z.
Limitations: Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.
Open this exact record in the library →Suggest a correctionOwner accepted PMID 42873315 as a source report. Evidence class stays Unresolved / evidence gap (U).
Context: Retatrutide literature queue. PMID 42873315. Reviewed 2026-10-21T07:15:29.785Z.
Limitations: Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.
Open this exact record in the library →Suggest a correctionOwner accepted PMID 42883986 as a source report. Evidence class stays Unresolved / evidence gap (U).
Context: Retatrutide literature queue. PMID 42883986. Reviewed 2026-10-21T07:14:55.745Z.
Limitations: Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.
Open this exact record in the library →Suggest a correctionOwner accepted PMID 42889249 as a source report. Evidence class stays Unresolved / evidence gap (U).
Context: Retatrutide literature queue. PMID 42889249. Reviewed 2026-10-21T07:15:09.879Z.
Limitations: Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.
Open this exact record in the library →Suggest a correctionOwner accepted PMID 42904878 as a source report. Evidence class stays Unresolved / evidence gap (U).
Context: Retatrutide literature queue. PMID 42904878. Reviewed 2026-10-23T08:20:25.747Z.
Limitations: Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.
Open this exact record in the library →Suggest a correctionOwner accepted PMID 42907720 as a source report. Evidence class stays Unresolved / evidence gap (U).
Context: Retatrutide literature queue. PMID 42907720. Reviewed 2026-10-23T08:20:40.574Z.
Limitations: Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.
Open this exact record in the library →Suggest a correctionOwner accepted PMID 42942810 as a source report. Evidence class stays Unresolved / evidence gap (U).
Context: Retatrutide literature queue. PMID 42942810. Reviewed 2026-10-27T18:45:14.990Z.
Limitations: Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.
Open this exact record in the library →Suggest a correctionOwner accepted PMID 42942813 as a source report. Evidence class stays Unresolved / evidence gap (U).
Context: Retatrutide literature queue. PMID 42942813. Reviewed 2026-10-27T18:45:30.957Z.
Limitations: Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.
Open this exact record in the library →Suggest a correctionOwner accepted PMID 42947668 as a source report. Evidence class stays Unresolved / evidence gap (U).
Context: Retatrutide literature queue. PMID 42947668. Reviewed 2026-10-28T15:50:03.293Z.
Limitations: Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.
Open this exact record in the library →Suggest a correctionOwner accepted PMID 42978208 as a source report. Evidence class stays Unresolved / evidence gap (U).
Context: Retatrutide literature queue. PMID 42978208. Reviewed 2026-11-08T03:42:51.620Z.
Limitations: Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.
Open this exact record in the library →Suggest a correctionAt week 80, placebo-adjusted AHI differences at 9 mg were -24.4 (TRIUMPH-1 OSA) and -14.4 (TRIUMPH-2 OSA) events/hour; at 12 mg, -21.9 and -15.1, respectively, under the hybrid estimand.
Context: Randomized placebo-controlled OSA subgroups: TRIUMPH-1 without diabetes n=243 and TRIUMPH-2 with diabetes n=448. The TRIUMPH-1 subgroup overlaps the earlier NEJM obesity paper and is not independent replication. Investigational once-weekly subcutaneous 4/9/12 mg arms studied over 80 weeks.
Limitations: Abstract-supported only. Full article, safety tables, attrition, escalation and statistical analysis plan not independently reconciled. Study doses are not recommendations; no approval or evidence-tier promotion implied.
Open this exact record in the library →Suggest a correctionThese compounds share an Atlas pathway label. That is a navigation connection, not evidence of equivalent effects or suitability together.
Browse this pathway in the library →Educational research summary. Study amounts are research context, not a dose recommendation. Not medical advice.